ReviewDiscover nano2026
Nanotechnology-enabled modulation of reactive oxygen species in cancer and chronic inflammation: a systematic review of therapeutic advances and translational challenges.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReactive oxygen species (ROS) are key regulators of cellular signalling and homeostasis, but if not managed, they can cause genomic instability, activation of carcinogenic pathways, and chronic inflammation. Approaches to ROS regulation using nanotechnology have demonstrated promise in preclinical models of inflammatory disorders and cancer but have yet to be transferred clinically due to concerns about specificity, safety, measurement, and standardization in redox regulation. MAIN BODY: The aim of this study was to assess nanotechnology strategies for achieving spatiotemporally controlled ROS modulation, highlighting technical challenges, safety issues, and translation barriers. We conducted a PRISMA 2020 systematic review (2013-2023) across PubMed, Scopus, and Web of Science. Eligible publications were screened using preset criteria; bias was assessed with SYRCLE. We synthesised nanomaterial classes, ROS-modulating mechanisms, therapeutic effects, and translational hurdles. We separately summarise findings for cancer and for chronic inflammation, then integrate convergences. Key findings include: ROS-induced genotoxic stress promotes malignant transformation and therapy resistance; persistent oxidative signalling enhances NF-κB/AP-1 activation and M1 polarisation, driving fibrosis and chronic inflammation. Harmonised procedures are necessary to address safety and standardisation issues, including chronic toxicity, immunogenicity, and inter-laboratory assay variation. Biomarker-stratified trials outperformed unstratified designs, and combination nanotherapies improved cancer cell kill over monotherapies.
conclusionNanotechnology-based ROS regulation is promising for cancer and chronic inflammatory illnesses but requires high-precision subcellular targeting, dual-threshold release, complete safety profiling, standardised ROS assays, and unified biomarker platforms for translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.